{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:47:13Z","timestamp":1777582033966,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To describe the clinical and optical coherence tomography (OCT) changes of prechoroidal cleft in treatment-na\u00efve and non-na\u00efve neovascular age-related macular degeneration (nAMD) treated with Faricimab intravitreal injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A case series (4 eyes from 4 patients).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cases 1 and 2 were diagnosed with treatment-na\u00efve nAMD. Case 1 showed minimal prechoroidal cleft persistence after treatment with visual acuity stabilization. Case 2 showed prechoroidal cleft resolution, followed by its recurrence with neovascular reactivation. Cases 3 and 4 had a history of nAMD unresponsive to Aflibercept therapy. In Case 3, prechoroidal cleft reappearance occurred simultaneously to neovascular reactivation. In Case 4 prechoroidal cleft resolved rapidly after switching to Faricimab, but this was complicated by the development of a retinal pigment epithelium (RPE) tear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this report, we highlight the importance of prechoroidal cleft as a negative prognostic OCT biomarker despite the increasingly proved efficacy of Faricimab. Pigment epithelium detachment height may correlate with the size of prechoroidal cleft and macular neovascularization (MNV) activity. Further studies are needed to better elucidate the prognostic significance of prechoroidal cleft after Faricimab therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721251322541","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T01:58:19Z","timestamp":1740621499000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Prechoroidal cleft changes after intravitreal injections of Faricimab in treatment-na\u00efve and nonresponders-to-aflibercept patients: A case series"],"prefix":"10.1177","volume":"35","author":[{"given":"Elisa","family":"Stradiotto","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Feo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9213-2834","authenticated-orcid":false,"given":"Giovanni","family":"Ottonelli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Del Turco","sequence":"additional","affiliation":[{"name":"Eye Unit, Humanitas-Gradenigo Hospital, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Panico","sequence":"additional","affiliation":[{"name":"Eye Unit, Humanitas-Gradenigo Hospital, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario R","family":"Romano","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"},{"name":"Department of Ophthalmology, Eye Unit Humanitas Gavazzeni-Castelli, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0733-9846","authenticated-orcid":false,"given":"Carlo","family":"La Spina","sequence":"additional","affiliation":[{"name":"Eye Unit, Humanitas-Gradenigo Hospital, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-14-159"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.08.019"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2023.10.013"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001435"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/11206721231185903"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15273"},{"key":"e_1_3_2_8_2","first-page":"2578349","article-title":"Prechoroidal cleft in type 3 neovascularization: incidence, timing, and its association with visual outcome","volume":"2018","author":"Kim JH","unstructured":"Kim JH, Chang YS, Kim JW, et al. Prechoroidal cleft in type 3 neovascularization: incidence, timing, and its association with visual outcome. J Ophthalmol 2018 Nov 19; 2018: 2578349.","journal-title":"J Ophthalmol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003242"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.2699"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-001702"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06421-0"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.06.024"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004316"},{"key":"e_1_3_2_16_2","article-title":"Modified pro re nata regimen of Brolucizumab in treatment-naive neovascular age-related macular degeneration","author":"Lippera M","unstructured":"Lippera M, Feo A, Del Turco C, et al. Modified pro re nata regimen of Brolucizumab in treatment-naive neovascular age-related macular degeneration. Retinal Cases & Brief Reports. 2024 Oct 28. doi:https:\/\/doi.org\/10.1097\/ICB.0000000000001692","journal-title":"Retinal Cases & Brief Reports."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2020.01.001"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05384-w"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251322541","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721251322541","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251322541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:47:19Z","timestamp":1777405639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721251322541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/11206721251322541"],"URL":"https:\/\/doi.org\/10.1177\/11206721251322541","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]}}}